Express News | Royalty Pharma: PTC Therapeutics Exercised Option to Sell Half of Retained Royalties on Roche's Evrysdi to Co's Unit for About $242 Mln Upfront

Reuters08:16 ET

Declining Stock and Decent Financials: Is The Market Wrong About Royalty Pharma Plc (NASDAQ:RPRX)?

Royalty Pharma (NASDAQ:RPRX) has had a rough three months with its share price down 8.9%. However, stock prices are usually driven by a company's financials over the long term, which in this case lo

Simply Wall StJun 13 15:57 ET

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash

BenzingaJun 12 09:15 ET

Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $50

Goldman Sachs analyst Chris Shibutani maintains $Royalty Pharma(RPRX.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 44.1% a

moomoo NewsJun 6 23:31 ET

Express News | Royalty Pharma:To Issue, Sell to Underwriters $500 Mln of Its 5.400% Senior Notes Due 2034 & $500 Mln of Its 5.900% Senior Notes Due 2059 in Offering

ReutersJun 4 17:08 ET

Express News | Royalty Pharma-on June 3,Entered Into Underwriting Deal, Co to Issue & Sell to Underwriters $500 Mln Amount of Its 5.150% Senior Notes Due 2029

ReutersJun 4 17:06 ET